Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

NCT03484819 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

NIH

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma

Interventions

DRUG: Copanlisib Hydrochloride
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)